MX2020012782A - Inhibidor de ccr5 para el uso en el tratamiento de cancer. - Google Patents

Inhibidor de ccr5 para el uso en el tratamiento de cancer.

Info

Publication number
MX2020012782A
MX2020012782A MX2020012782A MX2020012782A MX2020012782A MX 2020012782 A MX2020012782 A MX 2020012782A MX 2020012782 A MX2020012782 A MX 2020012782A MX 2020012782 A MX2020012782 A MX 2020012782A MX 2020012782 A MX2020012782 A MX 2020012782A
Authority
MX
Mexico
Prior art keywords
treating cancer
ccr5 inhibitor
ccr5
inhibitor
administering
Prior art date
Application number
MX2020012782A
Other languages
English (en)
Spanish (es)
Inventor
Oliver Hartley
Robin Ewart Offord
Original Assignee
ORION Biotechnology Switzerland Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORION Biotechnology Switzerland Sarl filed Critical ORION Biotechnology Switzerland Sarl
Publication of MX2020012782A publication Critical patent/MX2020012782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2020012782A 2018-05-28 2019-05-24 Inhibidor de ccr5 para el uso en el tratamiento de cancer. MX2020012782A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US201962792600P 2019-01-15 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
MX2020012782A true MX2020012782A (es) 2021-04-28

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012782A MX2020012782A (es) 2018-05-28 2019-05-24 Inhibidor de ccr5 para el uso en el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US20210205411A1 (https=)
EP (1) EP3813870B1 (https=)
JP (2) JP7319020B2 (https=)
KR (1) KR20210016398A (https=)
CN (1) CN112469429B (https=)
AU (1) AU2019276939A1 (https=)
BR (1) BR112020024328A2 (https=)
CA (1) CA3101556A1 (https=)
MX (1) MX2020012782A (https=)
WO (1) WO2019229616A1 (https=)
ZA (1) ZA202007955B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019405A2 (pt) * 2019-04-01 2021-11-30 Cytodyn Inc Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
ES2800316T3 (es) * 2011-06-13 2020-12-29 Tla Targeted Immunotherapies Ab Tratamiento del cáncer
JP6518585B2 (ja) * 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3212228B1 (en) * 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Also Published As

Publication number Publication date
CN112469429A (zh) 2021-03-09
JP2021525770A (ja) 2021-09-27
CA3101556A1 (en) 2019-12-05
EP3813870A1 (en) 2021-05-05
EP3813870C0 (en) 2023-11-15
BR112020024328A2 (pt) 2021-02-23
WO2019229616A1 (en) 2019-12-05
KR20210016398A (ko) 2021-02-15
EP3813870B1 (en) 2023-11-15
ZA202007955B (en) 2022-06-29
CN112469429B (zh) 2025-02-14
JP7319020B2 (ja) 2023-08-01
JP2023134704A (ja) 2023-09-27
US20210205411A1 (en) 2021-07-08
AU2019276939A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
ZA202007007B (en) Mcl-1 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
EP4302835A3 (en) Methods of treating ovarian cancer
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.